Business and Finance

Bayer said it will explore access options for patients with follicular lymphoma currently receiving Aliqopa who have experienced a favorable response to treatment.

Blue Fin Group exec speaks on his upcoming feature.

Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.

Blue Fin Group executive highlights how leaders can plan for immediate profitable lifecycles and beyond.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Session explains how to use this information to help bolster market intelligence, market access, and affordability strategies.

Conference presentation explores groundbreaking topics impacting the pharma industry.

Session explores how on-market products have done, and what to expect from new biosimilars.

Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.

New company to be publicly listed as Citius Oncology, Inc.

Investment offers opportunity to expand global footprint, company says.

Sector is anticipated to grow at a CAGR of 9.3%.

The Vicenza site will run about 54,000 square feet in size.

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging.

CDMO’s goal is to increase building’s aseptic manufacturing capacity.

Acquisition helps expand pharma marketing reach and opens door for growth opportunities.

The conference will focus on the full breadth of commercialization strategies and operations.

Acquisition includes company’s inflammatory disease medicines.

Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.

The newly established business under Advent International and Warburg Pincus will be named Simtra BioPharma Solutions.

Deal—expected to be finalized by the end of the year—grows the logistics provider’s healthcare capabilities.

Manufacturing capacity of company’s High Point facility now doubles as a result.

The latest people news happenings over the past month.

The trend is continuing for brands and even for some specialty products.

Shares expected to be offered on Six Swiss Exchange.

This would signify an 8.3% CAGR over the next five years.

Max Sauberschwarz will become the Group's newest EVP this October.

Strategy includes a layoff of nearly 400 employees.

Karin Van Den Brekel, Niall Walsh hired to manage EMEA and Ireland respectively.

Stephanie Smith Cooney joins PBM business to further develop partnerships, especially with independent pharmacists in local communities.